Resveratrol protects bone marrow mesenchymal stem cell derived chondrocytes cultured on chitosan-gelatin scaffolds from the inhibitory effect of interleukin-1beta.
OBJECTIVE
To investigate the effects of resveratrol on interleukin-1beta (IL-1beta) induced catabolism in bone marrow mesenchymal stem cell (MSC) derived chondrocytes cultured on chitosan-gelatin scaffolds (CGS).


METHODS
The chondrogenesis of alginate-encapsulated MSCs was evaluated by toluidine blue staining, RT-PCR, and immunostaing. MSC-derived chondrocyte morphology cultured on CGS was evaluated by a scanning electron microscope (SEM) and a laser confocal microscope (LCM). When these cells on CGS were pre-stimulated with IL-1beta or co-treated with IL-1beta and resveratrol in the absence and presence of the specific beta1-integrin blocking antibody, collagen type II, aggrecan, matrix metalloproteinase-13 (MMP-13) expression, and the translocation of nuclear factor kappaB (NF-kappaB) were analyzed by Western blot analysis.


RESULTS
Transforming growth factor beta 3 (TGF-beta3) combined with insulin-like growth factor I (IGF-I) induced the cartilage-specific collagen type II, aggrecan expression and extracellular matrix (ECM) accumulation at the end of a 3-week culture. CGS supported those differentiated chondrocytes'attachment, proliferation, migration, and ECM formation. When those cells cultured on CGS were stimulated with IL-beta1 alone, collagen type II and aggrecan expression was inhibited. However, MMP-13 expression increased. Resveratrol reversed the catabolic effects by reducing the translocation of NF-kappaB. A specific beta1-integrin blocking antibody abrogated the effects of resveratrol on IL-1beta stimulated MSC-derived chondrocytes.


CONCLUSIONS
These results indicated that resveratrol acts as a NF-kappaB inhibitor to protect MSC-derived chondrocytes on the CGS from the IL-1beta catabolism and these effects are mediated by beta1-integrin.
Lei
Ming
M
Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Liu
Shi-qing
SQ
Liu
Yu-Lan
YL
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000648:ultrastructure; D002478:Cells, Cultured; D048271:Chitosan; D019902:Chondrocytes / Q000187:drug effects* / Q000648:ultrastructure; D003470:Culture Media; D005780:Gelatin; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000648:ultrastructure; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000627:therapeutic use*; D054457:Tissue Scaffolds
D000975:Antioxidants; D003470:Culture Media; D053583:Interleukin-1beta; D013267:Stilbenes; D005780:Gelatin; D048271:Chitosan; D000077185:Resveratrol